We are Healthy
U.S.

Diabetes Drugs Found More Cost-Effective for MASH

New modeling suggests specific treatments for MASH offer greater value to U.S. patients than current options.

Updated on Sept. 29, 2026 in Diabetes

Bold flat-color editorial illustration featuring a glass vial and crystalline blocks, symbolizing the economic assessment of healthcare treatments.
A new health study suggests that semaglutide and tirzepatide provide better cost-effectiveness for MASH treatment than resmetirom, impacting future U.S. payer coverage. AI Illustration. Upload story photo >

Live Poll

Should federal policies prioritize lower drug prices to ensure wider patient access to new therapies?

A study published in September 2026 evaluated the cost-effectiveness of three common metabolic dysfunction-associated steatohepatitis (MASH) therapies. Researchers found that while semaglutide and tirzepatide met standard value benchmarks, resmetirom required significant price adjustments to reach the same threshold.

Why it matters

Understanding which MASH treatments offer the best economic value helps inform payer coverage and improves equitable access to care. As annual national spending for these therapies could exceed $10 billion, such analyses are critical for managing the long-term sustainability of patient treatment.

This lifetime Markov model analyzed 50-year-old adults with biopsy-confirmed MASH, using a Bayesian network meta-analysis to compare the three therapies against a placebo. The findings suggest that resmetirom would need a 61% price reduction to align with a $100,000 per QALY standard.

The players

Diabetes, Obesity and Metabolism

A peer-reviewed journal that publishes original research on the physiological and clinical aspects of metabolic disease.

The details

The study utilized a lifetime perspective to simulate the health outcomes and costs associated with chronic MASH management. By calculating the incremental cost-effectiveness ratio (ICER), the model weighed the health benefits, measured in quality-adjusted life-years, against the high annual acquisition costs of these medications. These figures provide a framework for how different therapeutic agents influence long-term system costs for patients requiring intervention for liver-related metabolic health.

Timeline

  1. Resmetirom gained FDA approval as a MASH therapy in 2024.

  2. Semaglutide received authorization for MASH treatment in August 2025.

  3. The cost-effectiveness study was released in September 2026.

Health Landscape

The use of the $100,000 per QALY cost-effectiveness threshold serves as a standard economic metric for evaluating new medical interventions. This study situates current MASH therapies against that benchmark to illustrate the financial viability of diverse treatment pipelines.

If you are managing MASH, these findings emphasize the importance of discussing with your doctor which treatment options provide the best balance of clinical efficacy and insurance sustainability. Understanding the value of your medication can assist in navigating coverage and long-term access to care.

The takeaway

Economic modeling helps identify which therapies offer the most sustainable health value for patients with MASH. Ask your physician about the clinical benefits of specific treatments and how they align with your insurance plan's coverage criteria.

Further reading

Learn more about evolving treatment standards in our Diabetes section.

Source note: This article includes information reported by Ajmc.

Live Poll

Should federal policies prioritize lower drug prices to ensure wider patient access to new therapies?